EYPT - EyePoint Pharmaceuticals, Inc.

6.78
0.410   6.047%

Share volume: 818,677
Last Updated: 04-28-2025
Measuring And Control Equipment/Lab Analytical Instruments: -0.04%

PREVIOUS CLOSE
CHG
CHG%
$6.37
0.41
0.06%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
13%
Profitability 0%
Dept financing 20%
Liquidity 72%
Performance 10%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
3.67%
1 Month
25.09%
3 Months
-12.29%
6 Months
-41.25%
1 Year
-61.54%
2 Year
2.11%
Key data
Stock price
$6.78
P/E Ratio 
0.00
DAY RANGE
$6.38 - $6.91
EPS 
-$2.32
52 WEEK RANGE
$3.91 - $21.26
52 WEEK CHANGE
-$61.48
MARKET CAP 
508.470 M
YIELD 
N/A
SHARES OUTSTANDING 
53.518 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-07-2025
BETA 
1.54
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$747,573
AVERAGE 30 VOLUME 
$894,702
Company detail
CEO: Nancy S. Lurker
Region: US
Website: eyepointpharma.com
Employees: 120
IPO year: 2008
Issue type: Common Stock
Market: XNAS
Industry: Measuring And Control Equipment/Lab Analytical Instruments
Sector: Manufacturing

EyePoint Pharmaceuticals, Inc. provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema. DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery. It is also developing EYP-1901, a twice-yearly bioerodible formulation of tyrosine kinase inhibitor for the. treatment of wet age-related macular degeneration, diabetic retinopathy and retinal vein occlusion.

Recent news
loading